China's Akeso Bets On IO Antibody Combo With First US IND

 
• By Brian Yang

Emerging Company Profile: Akeso's lead compound is the bispecific antibody AK104, which targets the checkpoints PD-1 and CTLA-4. It will be advanced globally with a first indication in gastric and gastroesophageal junction cancers. This is the first in a series of China-based emerging company profiles.

Emerging Company Profile Regular column feature image Version 2
Chinese Bioventure Akeso Has Obtained An IND For Its Lead Asset • Source: Shutterstock

More from Immuno-oncology

More from Anticancer